{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"A","limit":50},"count":50,"signals":[{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":14,"context":": (A) (1) is not and will not become a party to: (i) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the -2- corporation, and (ii) any Voting Commitment that could limi","filed_date":"2026-03-20","accession":"0001193125-26-117614","full_text":"https://origin.rootz.global/static/filing/0001193125-26-117614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":26,"context":"lidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSFiscal Year 2025 Plan (\"FY25 Plan\") In the second quarter of fiscal year 2025, we announced a restructuring plan designed to optimize our management structure to better serve our customers. The expense associated with this workforce reduction includes severance and other personnel-related costs. These actions i","filed_date":"2026-03-03","accession":"0001090872-26-000023","full_text":"https://origin.rootz.global/static/filing/0001090872-26-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nge. Further, additional tariffs, the scope and duration of which, if implemented, remain uncertain, and the potential commencement and escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2026-03-03","accession":"0001090872-26-000023","full_text":"https://origin.rootz.global/static/filing/0001090872-26-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":15,"context":"and compensation generally. The Compensation Committee receives reports from management and discusses whether our compensation policies and practices create risks that are reasonably likely to have a material adverse effect on the Company. The Compensation Committee also oversees risks relating to organization talent and culture and human capital management. The Nominating/Corporate Governance Committee oversees matters","filed_date":"2026-02-06","accession":"0001193125-26-040286","full_text":"https://origin.rootz.global/static/filing/0001193125-26-040286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":24,"context":"| | | | | | | | | Judy Gawlik Brown,Sue H. Rataj,George A. Scangos, Ph.D., andDow R. Wilson. | | | | | | | | | 2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | 3. | To ratify the Audit and Finance Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | | | 4.","filed_date":"2026-02-06","accession":"0001193125-26-040286","full_text":"https://origin.rootz.global/static/filing/0001193125-26-040286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":37,"context":"bligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic and market conditions, including relating to or arising from changes to tariffs, import/export or trade p","filed_date":"2025-12-22","accession":"0001090872-25-000087","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"lude instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. In addition, we conduct centralized order fulfillment and supply chain operations for our businesses through the order fulfillment and supply chain organization (\"OFS\"). OFSprovides resources for manufacturing, engineering and strategic sourcing to o","filed_date":"2025-12-22","accession":"0001090872-25-000087","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"margin_pressure","strength":100,"match_count":17,"context":"nistrative | $ | 641 | $ | 611 | $ | 633 | 5% | (4)% | | | Operating margin | 19.7 | % | 19.6 | % | 24.2 | % | | (5) ppts. | | | Income from operations | $ | 536 | $ | 484 | $ | 673 | 11% | (28)% | | Gross margin decreased 2 percentage points in 2025 when compared to 2024. Gross margin was impacted mainly by increased tariffs and shipping costs, unfavorable business mix (including lower gross margin from our specialty","filed_date":"2025-12-22","accession":"0001090872-25-000087","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":24,"context":"nge. Further, additional tariffs, the scope and duration of which, if implemented, remain uncertain, and the potential commencement and escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2025-12-22","accession":"0001090872-25-000087","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":24,"context":"re reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSSummary of Restructuring Plans. In fiscal year 2025, we announced a restructuring plan designed to optimize our management structure to better serve our customers. In fiscal years 2024 and 2023, we announced restructuring plans t","filed_date":"2025-08-29","accession":"0001090872-25-000036","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":9,"context":"nge. Further, additional tariffs, the scope and duration of which, if implemented, remain uncertain, and the potential commencement and escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2025-08-29","accession":"0001090872-25-000036","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":24,"context":"re reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSSummary of Restructuring Plans. In fiscal year 2025, we announced a restructuring plan designed to optimize our management structure to better serve our customers. In fiscal years 2024 and 2023, we announced restructuring plans t","filed_date":"2025-06-02","accession":"0001090872-25-000021","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":10,"context":". The impact of changes to tariffs and trade policies in the first half of fiscal year 2025 was not material. However, if tariffs are implemented as initially announced in April 2025, we anticipate a significant adverse impact on our future costs of revenue, which would impact our results of operations in the second half of fiscal year 2025. The ultimate impact of changes to tariffs and trade policies will depend on variou","filed_date":"2025-06-02","accession":"0001090872-25-000021","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":34,"context":"bligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic and market conditions, the recovery and health of our end markets, seasonality, mix, future financial res","filed_date":"2025-03-03","accession":"0001090872-25-000010","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"lude instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. In addition, we conduct centralized order fulfillment and supply chain operations for our businesses through the order fulfillment and supply chain organization (\"OFS\"). OFSprovides resources for manufacturing, engineering and strategic sourcing to o","filed_date":"2025-03-03","accession":"0001090872-25-000010","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":13,"context":"utics in Frederick, Colorado. Some of our investment may be eligible to qualify for reimbursement incentives, which will not fully be known until the expansion is substantially complete. In 2024, we invested $862 million primarily for our acquisition of BIOVECTRA and one other acquisition compared to $51 million for two acquisitions in 2023 and $52 million for our acquisition of Polymer Standards Service and advanced","filed_date":"2025-03-03","accession":"0001090872-25-000010","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":21,"context":"re reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSSummary of Restructuring Plans. In fiscal years 2024 and 2023, we announced restructuring plans that were both designed to reduce costs and expenses in response to macroeconomic conditions. These actions impact all three of our b","filed_date":"2025-03-03","accession":"0001090872-25-000008","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":10,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2025-03-03","accession":"0001090872-25-000008","full_text":"https://origin.rootz.global/static/filing/0001090872-25-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ve compensation and compensation generally. The Compensation Committee receives reports and discusses whether our compensation policies and practices create risks that are reasonably likely to have a material adverse effect on the company. The Compensation Committee also oversees risks relating to organization talent and culture and human capital management, including diversity and inclusion programs and initiatives. Th","filed_date":"2025-01-31","accession":"0000950170-25-011439","full_text":"https://origin.rootz.global/static/filing/0000950170-25-011439.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":23,"context":"tion as directors: | | | | | | | | | | Otis W. Brawley, M.D. andMikael Dolsten, M.D., Ph.D. | | | | | | | | | 2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | 3. | To ratify the Audit and Finance Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | | | 4.","filed_date":"2025-01-31","accession":"0000950170-25-011439","full_text":"https://origin.rootz.global/static/filing/0000950170-25-011439.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":34,"context":"bligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic and market conditions, the recovery and health of our end markets, seasonality, mix, future financial res","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"lecular level. The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes. In addition, we conduct centralized order fulfillment and supply chain operations for our businesses through the order fulfillment and supply chain organization (\"OFS\"). OFSprovides resources for manufacturing, engineering and strategic sourcing to o","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"ess with available markets and position ourselves to capture market share. Backlog We believe that backlog is not a meaningful indicator of future business prospects for our business segments since a significant portion of our revenue for a given quarter is derived from the current quarter's orders.Therefore, we believe that backlog information is not material to an understanding of our business. Intellectual Property We generate","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"margin_pressure","strength":100,"match_count":17,"context":"ive | $ | 788 | $ | 805 | $ | 829 | (2)% | (3)% | | | Operating margin | 27.3 | % | 29.9 | % | 30.2 | % | (3) ppts. | | | | Income from operations | $ | 877 | $ | 1,049 | $ | 1,097 | (16)% | (4)% | | Gross margin decreased 1 percentage point in 2024 compared to 2023. Gross margin was impacted by lower sales volume, unfavorable impact of currency movements and higher warranty costs which were partially offset by lower s","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":25,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":14,"context":"cs in Frederick, Colorado. Some of our investment may be eligible to qualify for reimbursement incentives, which will not fully be known until the expansion is substantially complete. 52 In 2024, we invested $862 million primarily for our acquisition of BIOVECTRA and one other acquisition compared to $51 million for two acquisitions in 2023 and $52 million for our acquisition of Polymer Standards Service and advanced","filed_date":"2024-12-20","accession":"0001090872-24-000049","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":15,"context":"to conduct the businesses in which they are engaged, except where the failure to be so qualified, in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position or results of operations of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under","filed_date":"2024-09-05","accession":"0001193125-24-214337","full_text":"https://origin.rootz.global/static/filing/0001193125-24-214337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":16,"context":"ur products, our sales, our purchase commitments, our capital expenditures, the integration and effects of our acquisitions and other transactions, savings and headcount reduction recognized from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic environment and geopolitical uncertainties, interest rate and inflationary pressures, that involve risks","filed_date":"2024-09-03","accession":"0001090872-24-000036","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"tive | $ | 397 | $ | 407 | $ | 378 | (3)% | 8% | | | Operating margin | 20.7 | % | 22.1 | % | 23.0 | % | (1) ppt. | (1) ppt. | | | Income from operations | $ | 363 | $ | 390 | $ | 381 | (7)% | 3% | | Gross margin decreased 2 percentage points in 2023 when compared to 2022. Gross margin decreased due to volume decline in our cell analysis and genomics businesses resulting in unfavorable business mix. Gross margin was al","filed_date":"2024-09-03","accession":"0001090872-24-000036","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":15,"context":"incentives, which will not fully be known until the expansion is substantially complete. 35 In 2023, proceeds from the divestiture of our Resolution Bioscience business were $50 million. In 2023, we invested $51 million for two acquisitions compared to $52 million for our acquisition of Polymer Standards Service and advanced artificial intelligence technology in 2022 and $547 million primarily related to the acquisi","filed_date":"2024-09-03","accession":"0001090872-24-000036","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":32,"context":"re reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSSummary of Restructuring Plans. In fiscal year 2024 and 2023, we announced restructuring plans that were both designed to reduce costs and expenses in response to recent macroeconomic conditions. These actions impact all three of","filed_date":"2024-08-30","accession":"0001090872-24-000033","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":9,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2024-08-30","accession":"0001090872-24-000033","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":19,"context":"act to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSIn the fourth quarter of fiscal year 2023, we initiated a restructuring plan (\"FY23 Plan\") designed to reduce costs and expenses in response to the current macroeconomic conditions. The plan included a reduction of our total headcount by approximately 400 regular employees, r","filed_date":"2024-06-03","accession":"0001090872-24-000021","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":9,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2024-06-03","accession":"0001090872-24-000021","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":15,"context":"act to our business, condensed consolidated financial condition, results of operations or cash flows.13. RESTRUCTURING AND OTHER RELATED COSTSIn the fourth quarter of fiscal year 2023, we initiated a restructuring plan (\"FY23 Plan\") designed to reduce costs and expenses in response to the current macroeconomic conditions. The plan included a reduction of our total headcount by approximately 400 regular employees, r","filed_date":"2024-03-05","accession":"0001090872-24-000011","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":9,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2024-03-05","accession":"0001090872-24-000011","full_text":"https://origin.rootz.global/static/filing/0001090872-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ve compensation and compensation generally. The Compensation Committee receives reports and discusses whether our compensation policies and practices create risks that are reasonably likely to have a material adverse effect on the company. The Compensation Committee also oversees risks relating to organization talent and culture and human capital management, including diversity and inclusion programs and initiatives. Th","filed_date":"2024-02-02","accession":"0000950170-24-010096","full_text":"https://origin.rootz.global/static/filing/0000950170-24-010096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":20,"context":": | | | | | | | | | | Mala AnandKoh Boon HweeMichael R. McMullen andDaniel K. Podolsky, M.D. | | | | | | | | | | 2.To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | | 3.To ratify the Audit and Finance Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | | | |","filed_date":"2024-02-02","accession":"0000950170-24-010096","full_text":"https://origin.rootz.global/static/filing/0000950170-24-010096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":15,"context":"ur products, our sales, our purchase commitments, our capital expenditures, the integration and effects of our acquisitions and other transactions, savings and headcount reduction recognized from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic environment and geopolitical uncertainties, interest rate and inflationary pressures, that involve risks","filed_date":"2023-12-20","accession":"0001090872-23-000020","full_text":"https://origin.rootz.global/static/filing/0001090872-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"ess with available markets and position ourselves to capture market share. Backlog We believe that backlog is not a meaningful indicator of future business prospects for our business segments since a significant portion of our revenue for a given quarter is derived from the current quarter's orders.Therefore, we believe that backlog information is not material to an understanding of our business. Intellectual Property We generate","filed_date":"2023-12-20","accession":"0001090872-23-000020","full_text":"https://origin.rootz.global/static/filing/0001090872-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"margin_pressure","strength":100,"match_count":18,"context":"istrative expenses increased due to higher wages and marketing expenses partially offset by lower sales commissions, variable pay and the favorable impact of currency movements when compared to 2021. Operating margin decreased 1 percentage point in 2023 compared to 2022. Operating margin was impacted by lower sales volume and the unfavorable impact of currency movements partially offset by lower variable pay and logistics","filed_date":"2023-12-20","accession":"0001090872-23-000020","full_text":"https://origin.rootz.global/static/filing/0001090872-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":11,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. 18 [Table of Contents](#i5efddf3cfb14402aaf972db895d49f6a_7) Most of our accounting and tax processes including general accounting, cos","filed_date":"2023-12-20","accession":"0001090872-23-000020","full_text":"https://origin.rootz.global/static/filing/0001090872-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":16,"context":"nt incentives, which will not fully be known until the expansion is substantially complete. In 2023, proceeds from the divestiture of our Resolution Bioscience business were $50 million. In 2023, we invested $51 million for two acquisitions compared to $52 million for our acquisition of Polymer Standards Service and advanced artificial intelligence technology in 2022 and $547 million primarily related to the acquisi","filed_date":"2023-12-20","accession":"0001090872-23-000020","full_text":"https://origin.rootz.global/static/filing/0001090872-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":14,"context":"(1) is not and will not become a party to: (i) any agreement, arrangement or understanding with, and has not given any commitment or -2- assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the corporation, and (ii) any Voting Commitment that could limit or","filed_date":"2023-05-22","accession":"0000950170-23-023437","full_text":"https://origin.rootz.global/static/filing/0000950170-23-023437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":15,"context":"•Heidi K. Kunz•Susan H. Rataj•George A. Scangos, Ph.D. and•Dow R. Wilson | | | | | | | | | | 2.To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | | 3.To ratify the Audit and Finance Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | |","filed_date":"2023-02-03","accession":"0000950170-23-001746","full_text":"https://origin.rootz.global/static/filing/0000950170-23-001746.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":10,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2022-12-21","accession":"0001090872-22-000026","full_text":"https://origin.rootz.global/static/filing/0001090872-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":15,"context":"| | | | | | | | Hans E. Bishop, Otis W. Brawley, M.D. and Mikael Dolsten, M.D., Ph.D. | | | | | | | | | | | | 2.To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | | | | 3.To ratify the Audit and Finance Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | |","filed_date":"2022-02-03","accession":"0001564590-22-003730","full_text":"https://origin.rootz.global/static/filing/0001564590-22-003730.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"margin_pressure","strength":100,"match_count":14,"context":"cs costs, higher intangible amortization expense and higher share-based compensation expense. Total gross margin for the year ended October31, 2020 decreased 1 percentage point when compared to 2019. Gross margin declined due to the impacts of pricing pressure, higher intangible amortization expense, higher wages, net unfavorable currency impact and higher fixed costs related to the new manufacturing facility in Frede","filed_date":"2021-12-17","accession":"0001090872-21-000027","full_text":"https://origin.rootz.global/static/filing/0001090872-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":10,"context":"l tariffs, the scope and duration of which, if implemented, remains uncertain, which have been proposed or threatened and the potential escalation of a trade war and retaliatory measures could have a material adverse effect on our business, results of operations and financial condition. Most of our accounting and tax processes including general accounting, cost accounting, accounts payable, accounts receivable and tax f","filed_date":"2021-12-17","accession":"0001090872-21-000027","full_text":"https://origin.rootz.global/static/filing/0001090872-21-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"A","company":"AGILENT TECHNOLOGIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":16,"context":"directors: | | | | | Mala Anand, Koh Boon Hwee, Michael R. McMullen and Daniel K. Podolsky, M.D. | | | | | | | | | | 2.To approve, on a non-binding advisory basis, the compensation of our named executive officers. | | | | | | | | | | 3.To ratify the Audit and Finance Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm. | | | | | | | | | |","filed_date":"2021-02-04","accession":"0001564590-21-004195","full_text":"https://origin.rootz.global/static/filing/0001564590-21-004195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"0e37570653f314b57729d942a29f9dedb254fc4b67c065dd02133cfbfe30260b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"6230062922781dd4fa89a0cce19623cdca9ba024554625ce7c4a483d19d34bd0","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":3,"hourly_limit":500,"remaining":497,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}